- Home
- SGA vs BMEA Comparison
SGA vs BMEA Comparison
Compare SGA & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGA
- BMEA
- Stock Information
- Founded
- SGA 1986
- BMEA 2017
- Country
- SGA United States
- BMEA United States
- Employees
- SGA N/A
- BMEA N/A
- Industry
- SGA Broadcasting
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- SGA Consumer Discretionary
- BMEA Health Care
- Exchange
- SGA Nasdaq
- BMEA Nasdaq
- Market Cap
- SGA 74.2M
- BMEA 65.8M
- IPO Year
- SGA 1992
- BMEA 2021
- Fundamental
- Price
- SGA $12.25
- BMEA $1.81
- Analyst Decision
- SGA
- BMEA Strong Buy
- Analyst Count
- SGA 0
- BMEA 10
- Target Price
- SGA N/A
- BMEA $22.30
- AVG Volume (30 Days)
- SGA 6.2K
- BMEA 5.2M
- Earning Date
- SGA 08-07-2025
- BMEA 07-30-2025
- Dividend Yield
- SGA 8.24%
- BMEA N/A
- EPS Growth
- SGA N/A
- BMEA N/A
- EPS
- SGA 0.55
- BMEA N/A
- Revenue
- SGA $111,837,000.00
- BMEA N/A
- Revenue This Year
- SGA N/A
- BMEA N/A
- Revenue Next Year
- SGA $4.84
- BMEA N/A
- P/E Ratio
- SGA $22.21
- BMEA N/A
- Revenue Growth
- SGA N/A
- BMEA N/A
- 52 Week Low
- SGA $10.75
- BMEA $1.29
- 52 Week High
- SGA $16.57
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- SGA 51.40
- BMEA 44.35
- Support Level
- SGA $12.13
- BMEA $2.24
- Resistance Level
- SGA $12.80
- BMEA $3.08
- Average True Range (ATR)
- SGA 0.44
- BMEA 0.40
- MACD
- SGA -0.05
- BMEA -0.03
- Stochastic Oscillator
- SGA 54.40
- BMEA 25.07
About SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.